Is Selling Stock Like Aurora Cannabis Inc After Such Decline Winning Strategy?

 Is Selling Stock Like Aurora Cannabis Inc After Such Decline Winning Strategy?

The stock of Aurora Cannabis Inc (CVE:ACB) is a huge mover today! About 6.57 million shares traded hands or 14.26% up from the average. Aurora Cannabis Inc (CVE:ACB) has risen 6.00% since November 1, 2016 and is uptrending. It has outperformed by 0.07% the S&P500. Despite the recent decline,  Aurora Cannabis is still probably a good stock to own. According to an analysis shared with us, Aurora has only had its sell license for less than a year and is now bringing in more than $1 million per month with 1,000’s of customers rapidly acquiring their medical marijuana license to buy from them. It is one of, if not the top capitalized licensed producers. The recent Q1/17 results were also robust. The decline recently is due to the upcoming Debenture  – meaning shares being released onto the market on Dec. 10, which is causing uncertainty about whether or not they will affect the share price temporarily.

More recent Aurora Cannabis Inc (CVE:ACB) news were published by: Seekingalpha.com which released: “Aurora Cannabis: Overvalued + A Misleading Management Team = SHORT” on November 08, 2016. Also Seekingalpha.com published the news titled: “Aurora Cannabis: Poised To Dominate Canadian Marijuana” on September 28, 2016. Seekingalpha.com‘s news article titled: “Aurora Cannabis: An Execution Story” with publication date: September 16, 2016 was also an interesting one.

Aurora Cannabis Inc. is engaged in the production and sale of medical cannabis. The company has a market cap of $707.68 million. The Firm is engaged in the business of producing and distributing medical marijuana pursuant to the Access to Cannabis for Medical Purposes Regulations . It currently has negative earnings. The Company’s product types include Tetrahydrocannabinol (THC), Cannabidiole (CBD), indica, sativa and hybrid.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment